FridayAug 27, 2021 1:30 pm

Portland Activists Call for Psychedelics to Be Decriminalized

Activists in Portland are calling for the city commission to approve a measure that would decriminalize the ceremonial use, gifting and growing of a number of psychedelics. This new measure would make community-based ceremonies and activities that involve entheogenic substances such as ibogaine and ayahuasca among the lowest law-enforcement priorities in Portland, Oregon. The activists, who are part of the PMHA (Plant Medicine Healing Alliance), worked with indigenous groups to draw up the initiative. This is why DMT extracted from toads and peyote were excluded from the initiative because of sustainability concerns. According to an overview, the draft initiative would…

Continue Reading

ThursdayAug 26, 2021 1:50 pm

What To Know Before Investing in the Psychedelic Industry

The burgeoning marijuana industry has presented numerous investment opportunities for individuals and companies alike. The psychedelic drug market, which is still immature, seems to be following this trend, with projections showing that its market size will have reached almost $11 billion by 2027. Most analysts agreewith a capital markets analyst from Canaccord Genuity, who estimates that psychedelic substances such as LSD and psilocybin could create an investment opportunity worth nearly $100 billion. Data from the CDC shows that the number of Americans suffering from suicidal thoughts, depression and anxiety almost doubled during the coronavirus pandemic. Numerous studies have also shown…

Continue Reading

WednesdayAug 25, 2021 12:45 pm

Psychedelic Clinical Trials in Europe to Advance Through Partnership with CROs

A new dawn in psychedelic research seems to be upon the pharmaceutical industry as we are witnessing partnerships between drug-development companies and contract research organizations. The partnerships are intended to speed up the drug-development process. For example, a partnership between Transpharmation and Clerkenwell Health will facilitate the advancement of psychedelic research in Europe as it will enable both clinical and preclinical trials to run simultaneously. It will also offer opportunities to drug developers working to bring psychedelic-inspired drugs to the market. In addition, such partnerships will provide coordinated and integrated methodology and support for every stage of psychedelic research. The…

Continue Reading

TuesdayAug 24, 2021 2:15 pm

Four Fungi Facts Revealed by Netflix Psychedelics Documentary

Psychedelics have become increasingly popular in the last few years as more studies on the substances are conducted by research institutions around the world. The most popular of these substances are LSD, MDMA and psilocybin mushrooms. If you’re yearning to know more about these substances and mushrooms and other fungi in general, but aren’t keen on reading papers in peer review journals, Netflix may be of use to you. The subscription-based streaming service has a documentary, titled “Fantastic Fungi.” that talks about different fungi, The documentary reveals interesting things about mushrooms, some of which aren’t commonly known. For instance, did…

Continue Reading

MondayAug 23, 2021 3:30 pm

Five Medical Benefits of Psychedelics

Research on psychedelics has found that the substances could be effectively used to treat various mental health conditions, including post-traumatic stress disorder and anxiety. But, what other therapeutic and medical benefits do psychedelics possess that may help humanity? Making organ transplants safer Ischemia-reperfusion injury, commonly referred to as IRI, occurs when organ tissues are damaged after being deprived of oxygen for some time. The inury can affect organs such as the brain, kidneys, lungs and the heart, and it mainly plagues patients who have undergone organ transplants. Physicians use machine perfusion and ischemic pre- and post-conditioning to reduce or prevent…

Continue Reading

MondayAug 23, 2021 10:44 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report

Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchange Cybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEO Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline Cybin (NEO: CYBN) (NYSE American: CYBN) is wrapping up a highly successful first quarter with the release of its Q1 2021 operational and financial report, for the period ended June 30, 2021 (https://ibn.fm/V9xNp). The biotech company, which is focused on progressing psychedelic therapeutics, hit some milestones this quarter,…

Continue Reading

FridayAug 20, 2021 2:00 pm

Salvia Divinorum: The Less-Known Psychedelic and Its Properties

The popularity of psychedelics has been growing as the research conducted on these substances for their therapeutic benefits increases. Substances such as DMT, LSD, MDMA and psilocybin are the most studied as well as the most common psychedelics while others, including salvia divinorum, aren’t popularly known. Salvia divinorum is a psychoactive plant used in rituals in Mazatec shamanic ceremonies. The plant species is found in the mountainous Sierra Mazateca area near Mexico’s Oaxaca City. Its leaves contain a compound known as salvinorin A, which induces the plant’s psychoactive effects when the leaves are smoked or chewed. This compound’s presence hinders…

Continue Reading

ThursdayAug 19, 2021 2:30 pm

Florida Researchers Seek Answers on Ability of Psychedelics to Treat Psychological Conditions

Research on psychedelic substances and the therapeutic properties they possess that can be used to treat various mental health conditions has been increasing. For example, researchers in Florida are focused on studying psilocybin, which is the active compound found in magic mushrooms. Earlier in 2019, the FDA granted breakthrough therapy status to psilocybin treatments under development, which made it easier for the Usona Institute, a nonprofit organization, to conduct studies on the psychedelic. Dr. Charles Raison, the institute’s director of clinical and translational research, stated that the organization had sites in seven states and was planning to establish a duo…

Continue Reading

ThursdayAug 19, 2021 11:56 am

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’

Delic is led by a best-in-class team of industry veterans with over 100 years of working knowledge in cannabis, finance, and psychedelic research The Vancouver-based company was formed in 2019 as the ‎first psychedelic umbrella platform The Delic self-sustaining Ecosystem covers three main areas: media, health, and science On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company, a legacy counterculture distributor of psychedelic media An estimated $238 billion is spent annually in the U.S. on mental health treatments and ancillary services University-led and FDA-approved studies are positioning North America as a leading region in the advancement…

Continue Reading

ThursdayAug 19, 2021 11:23 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Adelia Acquisition Making Impact, Reaching Milestones

Cybin subsidiary achieved certain milestones as outlined in acquisition agreement Adelia brought numerous advantages to company Acquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO Cybin's (NEO: CYBN) (NYSE American CYBN) most recent acquisition, Adelia Therapeutics Inc., is already reporting success for the company (https://ibn.fm/ZtWL2). Cybin recently announced that the wholly controlled subsidiary had achieved certain milestones for the year as outlined in the acquisition agreement, resulting in Adelia shareholders receiving common shares in Cybin. Cybin closed on the acquisition of Adelia late last year, with the company noting…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050